Prevalence and phenotype of the c.1529C>T SPG7 variant in adult-onset cerebellar ataxia in Italy.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
01 2019
Historique:
received: 09 02 2018
accepted: 07 08 2018
pubmed: 12 8 2018
medline: 4 6 2019
entrez: 12 8 2018
Statut: ppublish

Résumé

Hereditary ataxias are heterogeneous groups of neurodegenerative disorders, characterized by cerebellar syndromes associated with dysarthria, oculomotor and corticospinal signs, neuropathy and cognitive impairment. Recent reports have suggested mutations in the SPG7 gene, causing the most common form of autosomal recessive spastic paraplegia (MIM#607259), as a main cause of ataxias. The majority of described patients were homozygotes or compound heterozygotes for the c.1529C>T (p.Ala510Val) change. We screened a cohort of 895 Italian patients with ataxia for p.Ala510Val in order to define the prevalence and genotype-phenotype correlation of this variant. We set up a rapid assay for c.1529C>T using restriction enzyme analysis after polymerase chain reaction amplification. We confirmed the diagnosis with Sanger sequencing. We identified eight homozygotes and 13 compound heterozygotes, including two novel variants affecting splicing. Mutated patients showed a pure cerebellar ataxia at onset, evolving in mild spastic ataxia (alternatively) associated with dysarthria (~80% of patients), urinary urgency (~30%) and pyramidal signs (~70%). Comparing homozygotes and compound heterozygotes, we noted a difference in age at onset and Scale for the Assessment and Rating of Ataxia score between the two groups, supporting an earlier and more severe phenotype in compound heterozygotes versus homozygotes. The SPG7 c.1529C>T (p.Ala510Val) mutants accounted for 2.3% of cerebellar ataxia cases in Italy, suggesting that this variant should be considered as a priority test in the presence of late-onset pure ataxia. Moreover, the heterozygous/homozygous genotype appeared to predict the onset of clinical manifestation and disease progression.

Sections du résumé

BACKGROUND AND PURPOSE
Hereditary ataxias are heterogeneous groups of neurodegenerative disorders, characterized by cerebellar syndromes associated with dysarthria, oculomotor and corticospinal signs, neuropathy and cognitive impairment. Recent reports have suggested mutations in the SPG7 gene, causing the most common form of autosomal recessive spastic paraplegia (MIM#607259), as a main cause of ataxias. The majority of described patients were homozygotes or compound heterozygotes for the c.1529C>T (p.Ala510Val) change. We screened a cohort of 895 Italian patients with ataxia for p.Ala510Val in order to define the prevalence and genotype-phenotype correlation of this variant.
METHODS
We set up a rapid assay for c.1529C>T using restriction enzyme analysis after polymerase chain reaction amplification. We confirmed the diagnosis with Sanger sequencing.
RESULTS
We identified eight homozygotes and 13 compound heterozygotes, including two novel variants affecting splicing. Mutated patients showed a pure cerebellar ataxia at onset, evolving in mild spastic ataxia (alternatively) associated with dysarthria (~80% of patients), urinary urgency (~30%) and pyramidal signs (~70%). Comparing homozygotes and compound heterozygotes, we noted a difference in age at onset and Scale for the Assessment and Rating of Ataxia score between the two groups, supporting an earlier and more severe phenotype in compound heterozygotes versus homozygotes.
CONCLUSIONS
The SPG7 c.1529C>T (p.Ala510Val) mutants accounted for 2.3% of cerebellar ataxia cases in Italy, suggesting that this variant should be considered as a priority test in the presence of late-onset pure ataxia. Moreover, the heterozygous/homozygous genotype appeared to predict the onset of clinical manifestation and disease progression.

Identifiants

pubmed: 30098094
doi: 10.1111/ene.13768
doi:

Substances chimiques

Metalloendopeptidases EC 3.4.24.-
SPG7 protein, human EC 3.4.24.-
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-86

Subventions

Organisme : Telethon
ID : GGP12217
Pays : Italy

Informations de copyright

© 2018 EAN.

Auteurs

C Mancini (C)

Department of Medical Sciences, University of Torino, Turin, Italy.

E Giorgio (E)

Department of Medical Sciences, University of Torino, Turin, Italy.

A Rubegni (A)

Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy.

L Pradotto (L)

Division of Neurology and Neurorehabilitation, San Giuseppe Hospital, IRCCS Istituto Auxologico Italiano, Piancavallo, Italy.

S Bagnoli (S)

Department of Neuroscience, Psychology, Drug Research and Child's Health, University of Florence, Florence, Italy.

E Rubino (E)

Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy.

P Prontera (P)

Medical Genetics Unit, Hospital S. Maria della Misericordia, Perugia, Italy.

S Cavalieri (S)

Department of Medical Sciences, University of Torino, Turin, Italy.

E Di Gregorio (E)

Department of Medical Sciences, University of Torino, Turin, Italy.

M Ferrero (M)

Department of Medical Sciences, University of Torino, Turin, Italy.

E Pozzi (E)

Department of Medical Sciences, University of Torino, Turin, Italy.

E Riberi (E)

Department of Medical Sciences, University of Torino, Turin, Italy.

P Ferrero (P)

Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy.

P Nigro (P)

Clinica Neurologica, Azienda Ospedaliera - Università di Perugia, Perugia, Italy.

A Mauro (A)

Department of Neurosciences, University of Torino, Turin, Italy.

M Zibetti (M)

Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy.

A Tessa (A)

Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy.

M Barghigiani (M)

Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy.

A Antenora (A)

Department of Neurosciences, Federico II University, Naples, Italy.

F Sirchia (F)

Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.

S Piacentini (S)

Department of Neuroscience, Psychology, Drug Research and Child's Health, University of Florence, Florence, Italy.

G Silvestri (G)

Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
Università Cattolica del Sacro Cuore, Rome, Italy.

G De Michele (G)

Department of Neurosciences, Federico II University, Naples, Italy.

A Filla (A)

Department of Neurosciences, Federico II University, Naples, Italy.

L Orsi (L)

Department of Neuroscience and Mental Health, Città della Salute e della Scienza University Hospital, Turin, Italy.

F M Santorelli (FM)

Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy.

A Brusco (A)

Department of Medical Sciences, University of Torino, Turin, Italy.
Medical Genetics Unit, Città della Salute e della Scienza Hospital, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH